期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
125I放射性粒子在纵隔淋巴结转移中的应用
1
作者 刘志刚 张凯歌 +7 位作者 雷光焰 吕卫东 张曦 宋养荣 严丽 马红兵 王珺 程齐 《中国肿瘤临床》 CAS CSCD 北大核心 2019年第7期351-356,共6页
目的:探讨^125I放射性粒子植入治疗纵隔淋巴结转移的安全性和疗效观察。方法:回顾性分析陕西省肿瘤医院2014年6月至2018年6月53例采用CT引导下125I粒子植入治疗纵隔淋巴结转移患者,采用术前放射治疗计划系统(treatment planning system,... 目的:探讨^125I放射性粒子植入治疗纵隔淋巴结转移的安全性和疗效观察。方法:回顾性分析陕西省肿瘤医院2014年6月至2018年6月53例采用CT引导下125I粒子植入治疗纵隔淋巴结转移患者,采用术前放射治疗计划系统(treatment planning system,TPS)进行计划并术后验证,记录术中、术后并发症情况,观察生存质量改善情况,治疗后1、3、6个月,1、2年复查胸部CT随访,评估局部病灶控制情况,随访中位生存期及总生存期,并对生存预后及死亡原因等进行分析。结果:53例纵隔淋巴结转移瘤患者均顺利完成125I放射性粒子植入术,中位生存期为254天,1年生存率为48.67%,疗效评价完全缓解率(complete response,CR)+部分缓解率(partial response,PR)为83.02%(44/53);Cox模型多因素分析,生存预后与ECOG评分、植入时远处转移、植入后同期化疗、二次粒子植入等相关因素有关(P<0.05);术中、术后气胸和咯血的并发症发生率分别为20.75%(11/53)、13.21%(7/53),无一例患者死亡;植入后在咳嗽、气短、疼痛、声音嘶哑、呛咳和上腔静脉综合征等症状方面有60.00%~82.61%的缓解率。结论:CT引导下125I粒子植入治疗纵隔淋巴结转移,具有手术创伤小、疗效显著、安全性好和可行性高等优点,具有重要应用价值,值得临床进一步推广应用。 展开更多
关键词 纵隔淋巴结转移 近距离放射疗法 ^125I粒子
下载PDF
Lanthanide-semiconductor probes for precise imaging-guided phototherapy and immunotherapy
2
作者 Yanxing Wang weidong lü +2 位作者 Ruiyi Dai Bi lin Ruichan lv 《Journal of Bio-X Research》 2020年第4期193-204,共12页
Objective::Immunotherapy is an effective tumor treatment strategy.However,its long treatment cycle limits its wide application across all cancer types.In this study,we optimized upconversion nanoparticles and manganes... Objective::Immunotherapy is an effective tumor treatment strategy.However,its long treatment cycle limits its wide application across all cancer types.In this study,we optimized upconversion nanoparticles and manganese composite particles with a porous structure as a nanoplatform for synergistic photodynamic therapy(PDT)and photothermal therapy(PTT),and subsequent longer-term immunotherapy.Methods::The morphology,phase,and stability were first characterized to evaluate the biocompatibility of this material.The upconversion and near infrared II luminescence properties of the material and its stimuli-response effect were assessed from the absorbance and photoluminescence spectra.Phototherapy including PDT and PTT was demonstrated in vitro and in vivo,and immunotherapy was used to enhance the phototherapy.This study was approved by the Xi’an Jiaotong University,China(approval No.XJTULAC2020-585)on April 2,2020.Results::The nanoplatform showed good PDT and PTT effects with high upconversion luminescence,and exhibited a more sensitive glutathione response(detection limit:55μg/mL)using fluorescence recovery than that based on absorbance recovery,with the detection range extending up to 1.2 mg/mL.When the surface of the composite particles was modified with an anti-PD-L1 immune checkpoint inhibitor,it targeted A549 lung cancer cells.The resulting immune response enhanced the long-term anti-tumor effect of the therapy,especially in lung cancer patients with high PD-L1 expression.Conclusion::The designed composite can be simultaneously used to detect the glutathione concentration based on luminescence recovery in the tumor cells and as a theranostic nanoplatform for synergistic immuno-phototherapy when combined with an antibody. 展开更多
关键词 Anti-PD-L1 antibody GLUTATHIONE IMMUNOTHERAPY PHOTOTHERAPY upconversion nanoparticles
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部